Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
HOOKIPA Pharma Inc. - Common Stock
(NQ:
HOOK
)
2.020
-0.120 (-5.61%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about HOOKIPA Pharma Inc. - Common Stock
< Previous
1
2
Next >
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
November 14, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
November 11, 2024
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell...
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
October 31, 2024
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
October 30, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
September 24, 2024
Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
HOOKIPA Pharma Announces Board of Directors Changes
August 30, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
July 08, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
July 01, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
June 04, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
May 30, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
April 26, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
April 25, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
April 10, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 22, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
January 29, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
January 16, 2024
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
December 21, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
November 20, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
November 03, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
November 02, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
October 22, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.